For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
This kit is designed for the detection of binding between FCGR1 (CD64) and human IgG Fc fragment using a homogeneous AlphaLISA assay (no wash steps). This assay can facilitate the design and development of antibody therapeutics by using competitive binding.
The Fc-Gamma Receptors (FCGRs) are members of immunoglobulin superfamily and play a critical role in the function of therapeutic antibodies. FCGRs are divided into three classes Fc-Gamma Receptor 1 (CD64), FCGR1; Fc-Gamma Receptor 2 (CD32), FCGR2 and Fc-Gamma receptor 3 (CD16), FCGR3.
FCGR1 is a high affinity Fc-gamma receptor, also known as FCGR1A and CD64. FCGR1 is a transmembrane protein with three extracellular Ig-like domains, and it delivers an activating signal via the associated Fc R gamma accessory chain. FCGR1 permits the triggering of effector responses at low IgG concentrations typical of early immune responses.
The AlphaLISA detection of FCGR1 and IgG Fc fragment binding uses IgG Fc AlphaLISA Acceptor beads to capture the human FCGR1 and Streptavidin-coated Donor beads to capture the biotinylated human FCGR1. Donor beads and Acceptor beads come into proximity through IgG Fc fragment binding to FCGR1. Excitation of the Donor beads provokes the release of singlet oxygen that triggers a cascade of energy transfer reactions in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
|Assay Target Class||Fc-receptor|
|Product Brand Name||AlphaLISA|
|Shipping Condition||Blue Ice|
|Unit Size||500 Assay Points|
Therapeutic antibodies have proven to be effective and safe treatments for various diseases, and understanding the binding of therapeutic antibodies to Fc receptors provides insights into their mechanism of action (MOA), efficacy, and safety. During early drug development, as potential therapeutic antibodies are selected and engineered, changes in Fc receptor affinity can be indicative of changes in effector function and serum half-life.
In this application note, we demonstrate how AlphaLISA® biochemical Fc receptor binding assays provide easy, robust methods to measure the binding of potential therapeutic antibodies to human Fc receptor proteins.